WFA
MAZE

WestHill Financial Advisors’s Maze Therapeutics MAZE Stock Holding History

WestHill Financial Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,186
Closed -$215K – 84
2025
Q4 		$215K Buy
+5,186
New +$178K 0.04% 76

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

WestHill Financial Advisors's MAZE Position: Q1 2026 in Review

WestHill Financial Advisors sold out of Maze Therapeutics (MAZE) in Q1 2026, closing a stake of 5,186 shares — an estimated $215K sold.

WestHill Financial Advisors first reported a position in MAZE in Q4 2025 and held it in 1 quarter. The position peaked at $215K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • WestHill Financial Advisors reported no remaining Maze Therapeutics position as of Q1 2026 after selling out during the quarter.
  • WestHill Financial Advisors sold 5,186 Maze Therapeutics shares in Q1 2026, an estimated $215K.
  • WestHill Financial Advisors first reported a position in Maze Therapeutics in Q4 2025 and held it in 1 quarter.
  • WestHill Financial Advisors's Maze Therapeutics position peaked at $215K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on WestHill Financial Advisors's 13F filing for Q1 2026, filed 9 Apr 2026.